December 13, 2021 07:15 AM EST

Generic drugs and biosimilars get last-minute reprieve from rebates with Senate tweaks to Build Back Better Act

Zachary Brennan

Senior Editor

The Senate Finance Committee on Saturday released the latest text of President Joe Biden’s $2 trillion spending package, paid for at least in part with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Generic drugs and biosimilars get last-minute reprieve from rebates with Senate tweaks to Build Back Better Act

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Gener­ic drugs and biosim­i­lars get last-minute re­prieve from re­bates with Sen­ate tweaks to Build Back Bet­ter Act

Senior Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Generic drugs and biosimilars get last-minute reprieve from rebates with Senate tweaks to Build Back Better Act